Evaluation of the dual peroxisome proliferator–activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial

✍ Scribed by Lincoff, A. Michael; Tardif, Jean-Claude; Neal, Bruce; Nicholls, Stephen J.; Rydén, Lars; Schwartz, Gregory G.; Malmberg, Klas; Buse, John B.; Henry, Robert R.; Wedel, Hans; Weichert, Arlette; Cannata, Ruth; Grobbee, Diederick E.

• Book ID: 121320628
• Publisher: Elsevier Science
• Year: 2013
• Tongue: English
• Weight: 166 KB
• Volume: 166
• Category: Article
• ISSN: 1097-6744
• DOI: 10.1016/j.ahj.2013.05.013